SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$40.95 USD
+0.85 (2.12%)
Updated Apr 22, 2024 11:54 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SWTX 40.95 +0.85(2.12%)
Will SWTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SWTX
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet
Other News for SWTX
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Cantor sees strong year ahead for oncology M&A
Cantor Fitzgerald sees strong year ahead for oncology M&A